Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.60 |
| ▸ | BMP4 | P12644 | 5/20 | 0.58 |
| ▸ | FLT1 | P17948 | 3/20 | 0.58 |
| ▸ | FLT4 | P35916 | 3/20 | 0.58 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.53 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.53 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.53 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.53 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.53 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13818131 | 0.89 | KDR (0.52) | KDRBMP4FLT1FLT4MAOB | |
| SCHEMBL4479049 | 0.86 | KDR (0.59) | KDRBMP4FLT1FLT4BMPR1B | |
| SCHEMBL4477345 | 0.84 | KDR (0.62) | KDRBMP4FLT1FLT4BMPR1B | |
| SCHEMBL4477974 | 0.84 | KDR (0.57) | KDRBMP4FLT1FLT4BMPR1B | |
| SCHEMBL640295 | 0.81 | CYP11B1 (0.60) | KMT2AMAP4K4MKNK2MAOB | |
| SCHEMBL4469276 | 0.80 | KDR (0.57) | KDRBMP4FLT1FLT4BMPR1B | |
| SCHEMBL4477194 | 0.80 | PDE2A (0.57) | KDRBMP4FLT1FLT4BMPR1B | |
| SCHEMBL13126019 | 0.77 | KDR (0.76) | KDRBMP4FLT1FLT4BMPR1B | |
| SCHEMBL4479183 | 0.76 | KDR (0.58) | KDRBMP4FLT1FLT4KMT2A | |
| SCHEMBL7610653 | 0.76 | KDR (1.00) | KDRBMP4FLT1FLT4BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20060025426-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | claimed |
| WO-2004052315-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060025426-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| WO-2004052315-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025426-A1 | Tyrosine kinase inhibitors | FLT1, FLT4, KDR | KDR 3/4885BMP4 2059/4885FLT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.